AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Perrigo on Pace for Largest Percent Decrease Since May 2024 -- Data Talk
Insiders At Perrigo Sold US$2.3m In Stock, Alluding To Potential Weakness
Trump's Medical Tariffs Could Significantly Hurt These European Healthcare Firms
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Insider Sale: EVP of $PRGO Sells 7,800 Shares
Trending Stocks Today | Plus Therapeutics Inches up 7.63% Post-Market
Perrigo To Go Ex-Dividend On March 7th, 2025 With 0.29 USD Dividend Per Share
Perrigo (NYSE:PRGO) Shareholders Are up 15% This Past Week, but Still in the Red Over the Last Five Years
Is Perrigo (PRGO) the Best Weight Loss Drug Stock to Buy According to Analysts?
Jefferies Initiates Perrigo(PRGO.US) With Hold Rating, Announces Target Price $31
Perrigo Company: Strategic Initiatives and Positive Financial Outlook Drive Buy Rating
Why Perrigo Company Plc (PRGO) Soared on Friday
Perrigo | 10-K: FY2024 Annual Report
Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y